Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Intercept Pharmaceuticals Inc
ICPT
Healthcare
Biotechnology
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic steatohepatitis (NASH), OCA and Bezafibrate, and Other...
Product Candidates. The Company’s marketed product, Ocaliva, is a farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. The Company is evaluating tolerability of OCA in combination with bezafibrate in patients with PBC in a Phase II study outside of the United States. Its other compounds are in early stages of research and development pipeline including INT-787 compound, an FXR agonist is in a Phase IIa clinical trial.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:ICPT)
New Post
View:
Posts & Comments
Threaded Posts
(4)
•••
AviseAnalytics
X
View Profile
View Bullboard History
Post by
AviseAnalytics
on Feb 11, 2022 7:34am
CAN INTERCEPT MAKE IT TO THE FINISHING LINE IN NASH?
$ICPT Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) is a biopharmaceutical Company aiming to create novel therapeutics for the treatment of progressive non-viral liver diseases. The Company has
...more
(4)
•••
AviseAnalytics
X
View Profile
View Bullboard History
Post by
AviseAnalytics
on Feb 08, 2022 9:03am
5 BIOTECH STOCKS WITH MAJOR UPCOMING CATALYSTS
$ICPT $CYTK $ADGI $PHAT $AGIO Clinical-Stage companies offer an exciting investment opportunity with massive upside potential. Most of these companies bring new and highly
...more
Viva Gold: Multiple High-Grade Gold Hits Includes 90 Meters at 2.0 gpt Gold
posted May 05, 2024 9:00am by
Viva Gold Corp.
-
|
TG2409 (21.3 meters at 5.1 gpt Au) was drilled as an approximate 40-meter offset to the west of TG2211 (57.9-meters at 5.0 gpt Au commencing at 40 meters depth). TG2408 (18.3 meters at 4.4 gpt Au). TG2407 (89.9 meters@ 2.0 gpt Au). TG2404 (36.6 Meters @ 3.3 gpt Au). “Many geologists go their whole careers without seeing drill results like these ...read more
(293)
•••
scarlet1967
X
View Profile
View Bullboard History
Post by
scarlet1967
on May 26, 2021 7:41pm
Please take a look
https://www.change.org/p/fda-and-ema-improving-the-public-health?recruiter=1170861947&recruited_by_id=6f0edee0-47cf-11eb-a646-01144e979023&utm_source=share_petition&utm_medium=copylink&
...more
(0)
•••
LiverTherapy
X
View Profile
View Bullboard History
Post by
LiverTherapy
on Feb 20, 2019 10:27am
Prediction
https://seekingalpha.com/instablog/24010943-first-genesis-consulting/5272843-newsletter-9-predictions-intercept-phase-3-nash-fibrosis-feb-8-2019-2-42-pm-et-comment
(0)
•••
LiverTherapy
X
View Profile
View Bullboard History
Post by
LiverTherapy
on Feb 07, 2019 4:41pm
ICPT
https://seekingalpha.com/instablog/24010943-first-genesis-consulting/5268535-intercept-pharmaceuticals-obeticholic-acid-nash-s-next
(0)
•••
LiverTherapy
X
View Profile
View Bullboard History
Post by
LiverTherapy
on Feb 05, 2019 3:30pm
NASH Progression In A Healthy Liver
https://stockhouse.com/blogs/nash-progression-in-a-healthy-liver
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Significant New Silver Discoveries in the Famous Keno Hill District in the Yukon
An Opportunity to Join Pulsar Helium on the Ground in Minnesota for a Historic Reservoir Flow Test